N/A N=60 Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Lung Diseases · Medication Compliance
Primary: Forced Oscillation Technique (FOT) Measures — 4.4; 3.7; 1.0; 0.6 resonant frequency
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
Ovarian Carcinoma · Endometrial Carcinoma · Cervical Carcinoma
Primary: Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 30.4; 36.4; 24.0; 33.3…
N/A N=60 Evaluation of Capillary Refill Index
Perfusion; Complications
Primary: Predictive Capability of the Altered Peripheral Perfusion — 0.89; 1.00; 0.94; 0.82 probability
Phase 2 N=30 Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Diffuse Large Cell Lymphoma · Lymphoma
Primary: Number of Participants With a 2-Year Progression-Free Survival (PFS) — 6; 8; 8; 5 Participants
N/A N=194 Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
Respiratory Tract Infections · Influenza, Human · Common Cold
Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants
Phase 3 N=136 Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
Active Rheumatoid Arthritis
Primary: Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24 — 63; 63 percentage of participants
Phase 2 N=70 Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Blastic Phase · Childhood Acute Promyelocytic Leukemia With PML-RARA · Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level — 0; 0; 5; 1 Participants
Phase 2 N=281 Open-label Extension Study Of RN624
Osteoarthritis · OA Knee Pain · Arthritis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 168; 8 Participants
Phase 4 N=18 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
Meningococcal Infections
Primary: Breadth of Protective Activity of Serum Anti-FHbp Antibody Responses of Adults Immunized With Trumenba Vaccine as Assessed by Serum Bactericidal Titers — 93 percentage…
Phase 3 N=253 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants
N/A N=11 Fundamental Asynchronous Stimulus Timing Sound Coding Study
Sensorineural Hearing Loss
Primary: Change in Open Set Monosyllabic Word Recognition Score — 5; 11.8; 20.2; 21.4 percentage of words correct
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Phase 2 N=223 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent…
N/A N=186 A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1C — 8.5; 9.4 mean percentage of HbA1c
N/A N=22 A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse
Dry Mouth
Primary: Product Performance and Attributes (PPAQ I) Question #1: 2-hr at Day 4 — 1.79; 2.97; 3.33 units on a scale